Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (58)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hulkkonen, J.
Right arrow Articles by Hurme, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hulkkonen, J.
Right arrow Articles by Hurme, M.
Related Collections
Right arrow Immunogenetics
Right arrow Sjogren's Syndrome
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2001; 40: 656-661
© 2001 British Society for Rheumatology

Original Papers

Elevated interleukin-6 plasma levels are regulated by the promoter region polymorphism of the IL6 gene in primary Sjögren's syndrome and correlate with the clinical manifestations of the disease

J. Hulkkonen, M. Pertovaara1, J. Antonen1,2, A. Pasternack1,2 and M. Hurme1,2

Institute of Medical Technology, University of Tampere,
1 Tampere University Hospital, Tampere and
2 University of Tampere Medical School, Tampere, Finland

Objectives. To determine whether plasma interleukin-6 (IL-6) and G/C base exchange polymorphism at position -174 of the IL6 gene have an effect on the clinical manifestations of primary Sjögren's syndrome (pSS).

Methods. Levels of circulating IL-6 protein and polymorphism of the IL6 gene were analysed in 66 patients with pSS and in 400 healthy subjects. These data were studied in relation to clinical data on the pSS patients.

Results. Plasma IL-6 was elevated in pSS patients compared with healthy controls. pSS patients with coeliac disease, pulmonary fibrosis or alveolitis or peripheral nervous system symptoms had significantly higher IL-6 levels than patients without these manifestations. IL-6 levels increased in parallel with the histological grade of minor salivary gland biopsy and the number of pSS criteria fulfilled. IL6 allele frequencies were similar in patients and normal subjects. Plasma IL-6 levels were regulated by the IL6 genotype in pSS patients.

Conclusions. The G/C polymorphism of the IL6 gene does not predispose patients to pSS, but the circulating IL-6 concentration is related to specific manifestations of the disease and the levels of IL-6 are regulated by the IL6 promoter polymorphism in pSS.

KEY WORDS: Autoimmunity, IL-6, Sjögren's syndrome, Cytokines, Genetics, Polymorphism.

Correspondence to: J. Hulkkonen, Department of Microbiology and Immunology, Medical School, University of Tampere, FIN-33014, Finland.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Res.Home page
A. DeMichele, R. Gray, M. Horn, J. Chen, R. Aplenc, W. P. Vaughan, and M. S. Tallman
Host Genetic Variants in the Interleukin-6 Promoter Predict Poor Outcome in Patients with Estrogen Receptor-Positive, Node-Positive Breast Cancer
Cancer Res., May 15, 2009; 69(10): 4184 - 4191.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
A. Oberbach, S. Lehmann, K. Kirsch, J. Krist, M. Sonnabend, A. Linke, A. Tonjes, M. Stumvoll, M. Bluher, and P. Kovacs
Long-term exercise training decreases interleukin-6 (IL-6) serum levels in subjects with impaired glucose tolerance: effect of the -174G/C variant in IL-6 gene
Eur. J. Endocrinol., August 1, 2008; 159(2): 129 - 136.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Sekiguchi, T. Iwasaki, M. Kitano, H. Kuno, N. Hashimoto, Y. Kawahito, M. Azuma, T. Hla, and H. Sano
Role of Sphingosine 1-Phosphate in the Pathogenesis of Sjogren's Syndrome
J. Immunol., February 1, 2008; 180(3): 1921 - 1928.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
M. Ramos-Casals and J. Font
Primary Sjogren's syndrome: current and emergent aetiopathogenic concepts
Rheumatology, November 1, 2005; 44(11): 1354 - 1367.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
M. Cardellini, L. Perego, M. D'Adamo, M. A. Marini, C. Procopio, M. L. Hribal, F. Andreozzi, S. Frontoni, M. Giacomelli, M. Paganelli, et al.
C-174G Polymorphism in the Promoter of the Interleukin-6 Gene Is Associated With Insulin Resistance
Diabetes Care, August 1, 2005; 28(8): 2007 - 2012.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
M. Weger, I. Steinbrugger, A. Haas, W. Marz, Y. El-Shabrawi, W. Weger, O. Schmut, and W. Renner
Role of the Interleukin-6 -174 G>C Gene Polymorphism in Retinal Artery Occlusion
Stroke, February 1, 2005; 36(2): 249 - 252.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
J. Hulkkonen, M. Pertovaara, J. Antonen, A. Pasternack, M. Hurme, P. Pollanen, and T. Lehtimaki
Matrix metalloproteinase 9 (MMP-9) gene polymorphism and MMP-9 plasma levels in primary Sjogren's syndrome
Rheumatology, December 1, 2004; 43(12): 1476 - 1479.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
M. Pertovaara, T. Lehtimaki, R. Rontu, J. Antonen, A. Pasternack, and M. Hurme
Presence of apolipoprotein E {epsilon}4 allele predisposes to early onset of primary Sjogren's syndrome
Rheumatology, December 1, 2004; 43(12): 1484 - 1487.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
M. Pertovaara, J. Hulkkonen, M. Hurme, T. Lehtimaki, and A. Pasternack
Urinary matrix metalloproteinase-9 and interleukin-6 and renal manifestations of primary Sjogren's syndrome
Rheumatology, June 1, 2004; 43(6): 807 - 808.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
M. Pertovaara, J. Hulkkonen, J. Antonen, P. Holopainen, P. Laippala, A. Pasternack, and M. Hurme
Polymorphism of the tumour necrosis factor-{alpha} gene at position -308 and renal manifestations of primary Sjogren's syndrome
Rheumatology, January 1, 2004; 43(1): 106 - 107.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
A. DeMichele, A.-M. Martin, R. Mick, P. Gor, L. Wray, M. Klein-Cabral, G. Athanasiadis, T. Colligan, E. Stadtmauer, and B. Weber
Interleukin-6 -174G->C Polymorphism Is Associated with Improved Outcome in High-Risk Breast Cancer
Cancer Res., November 15, 2003; 63(22): 8051 - 8056.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
D. Harding, S. Dhamrait, A. Millar, S. Humphries, N. Marlow, A. Whitelaw, and H. Montgomery
Is Interleukin-6 -174 Genotype Associated With the Development of Septicemia in Preterm Infants?
Pediatrics, October 1, 2003; 112(4): 800 - 803.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
O. P. Kristiansen, R. L. Nolsoe, L. Larsen, A. M.P. Gjesing, J. Johannesen, Z. M. Larsen, A. E. Lykkesfeldt, A. E. Karlsen, F. Pociot, T. Mandrup-Poulsen, et al.
Association of a functional 17{beta}-estradiol sensitive IL6-174G/C promoter polymorphism with early-onset type 1 diabetes in females
Hum. Mol. Genet., May 15, 2003; 12(10): 1101 - 1110.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
A. Kubaszek, J. Pihlajamaki, K. Punnonen, P. Karhapaa, I. Vauhkonen, and M. Laakso
The C-174G Promoter Polymorphism of the IL-6 Gene Affects Energy Expenditure and Insulin Sensitivity
Diabetes, February 1, 2003; 52(2): 558 - 561.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
J. Hulkkonen, M. Pertovaara, J. Antonen, A. Pasternack, and M. Hurme
IL-1 gene family haplotypes and Raynaud's phenomenon in primary Sjogren's syndrome
Rheumatology, October 1, 2002; 41(10): 1206 - 1208.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.